UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported) June 13, 2012
 
Progenics Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
 
Delaware
 
000-23143
 
13-3379479
(State or other jurisdiction
of incorporation)
 
(Commission
File Number)
 
(IRS Employer
Identification No.)
         
777 Old Saw Mill River Road, Tarrytown, New York
 
10591
(Address of principal executive offices)
 
(Zip Code)
Registrant's telephone number, including area code (914) 789-2800
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
 
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 
 

 

Item 5.07. Submission of Matters to a Vote of Security Holders.

Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) held its 2012 Annual Meeting of Stockholders on June 13, 2012. At the Meeting stockholders voted on (i) the election of directors; (ii) an advisory vote on the compensation of the Company’s named executive officers, (iii) amendment of its 2005 Stock Incentive Plan to increase the number of common shares available for issuance from 7,450,000 to 8,450,000, and (iv) ratification of the Board of Directors’ selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for 2012. The number of votes cast for and against, and abstentions and broker non-votes with respect to each matter are set forth below.
 
   
For
 
Against
 
Abstain
 
Broker Non-Votes
 1.  Election of Directors
             
 4,566,402
  Charles A. Baker
 
26,537,186
 
390,307
 
7,595
   
  Mark R. Baker
 
26,757,241
 
169,002
 
8,845
   
  Kurt W. Briner
 
26,769,949
 
157,544
 
7,595
   
  Peter J. Crowley
 
26,579,231
 
348,262
 
7,595
   
  Stephen P. Goff
 
24,975,499
 
1,951,994
 
7,595
   
  Paul J. Maddon
 
26,750,607
 
177,230
 
7,251
   
  David A. Scheinberg
 
26,781,201
 
146,292
 
7,595
   
  Nicole S. Williams
 
26,810,130
 
117,164
 
7,794
   
                 
2.  Advisory vote on compensation of named executive officers
 
26,441,354
 
384,867
 
108,867
 
4,566,402
                 
3.  Stock Incentive Plan amendment
 
23,137,981
 
3,788,836
 
8,271
 
4,566,402
                 
4.  Ratification of selection of Ernst & Young LLP
 
31,378,318
 
103,362
 
19,810
 
0




 
 

 

SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
                         PROGENICS PHARMACEUTICALS, INC.
                         By:  /s/ ROBERT A. MCKINNEY                            
                            Robert A. McKinney
                            Chief Financial Officer, Senior Vice President,
                            Finance & Operations
 
 
 
Date:  June 15, 2012